One group used The Cancer Genome Atlas to identify methylation of a CpG site at complement component 1 subcomponent R (C1R) as a prognostic biomarker for OS in AML patients, related to chromatin organization rather than gene expression levels of C1R [99]. Here, C1R is linked to acute myeloid leukemia.